Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.53, read 2026-10-23
Ethical does not pass the values gate
Price257.57 USD
Fair value144.70
Ethical score70.0/100
RatingAVOID
Our investment reviews on this name
2026-10-22Read Distribution244.57+5.3% to today Markup gives way to Distribution after a 17% rise in 9 weeks
2026-08-19Read Markup209.86+22.7% to today ✓Accumulation gives way to Markup after a 69% slide in 7 weeks
2026-07-02Read Accumulation671.02-61.6% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
CrowdStrike holds its Distribution at $257.57. The statistical read favours the sellers, held for 38 days.
As held on the ledger · 2026-10-23
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 38 days
Price at the screen
$257.57
Valuation
4,891.40 trailing · 151.79 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.20
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
7.40%
Below 33%
Interest-bearing debt is just 7.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.69%
Below 33%
Cash held in interest-bearing accounts and securities is 0.7% of assets, under the one-third limit.
Pass
Receivables
59.46%
Below 49%
Money owed to the company is 59.5% of assets, above the 49% limit.
Fail
Revenue purity
4.05%
Below 5%
Only 4.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
CrowdStrike's business is fine, but its receivables are about 59% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CRWD's ethical verdict changes
Today CRWD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades above our $144.70 fair value estimate, weak competitive moat, 25.80% revenue growth.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. The price runs 40.8% above the base estimate.
Third-party analyst targets: 50 covering, consensus Buy. The average target sits −4% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cloud Security Giant Fails Ethical Standards
Imagine a world where every digital footstep is a target for cyber threats; CrowdStrike stands as a fortress, protecting businesses with its cybersecurity solutions. However, for all its technological prowess, CrowdStrike fails to meet our ethical standards, specifically in managing accounts receivable, leading to a FAIL on our ethical screen.
Despite presenting an impressive 26% revenue growth and a forward P/E of 121.4x, CrowdStrike's profitability remains elusive with a profit margin of -1% and a return on equity (ROE) of 0%. This financial performance, coupled with a weak moat and a stock price well above our fair value of $125.94, raises concerns about the investment's sustainability and the margin of safety.
The consensus rating from 50 analysts is a buy, with a median target price of $211. However, given the ethical failings and the current valuation, we advise caution. The risks are significant, especially considering the ethical dimension, which is non-negotiable from our perspective. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CRWD trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (51 analysts) rates it buy, with a mean price target of $535. Insiders have been net sellers over the past quarter.
2026-10-15Markup$275.04+9.1%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (51 analysts) rates it buy, with a mean price target of $535. Insiders have been net sellers over the past quarter.
2026-10-02Markup$252.13+32.5%Entry 13
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 32.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (51 analysts) rates it buy, with a mean price target of $535. Insiders have been net sellers over the past quarter.
2026-08-26Markup$190.34+0.0%Entry 12
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (51 analysts) rates it buy, with a mean price target of $535. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Markup$190.34+0.0%Entry 11
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (51 analysts) rates it buy, with a mean price target of $535. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-24Markup$190.34+0.0%Entry 10
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (51 analysts) rates it buy, with a mean price target of $535. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Markup$190.34+0.0%Entry 9
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (51 analysts) rates it buy, with a mean price target of $535. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-22Markup$190.34+0.0%Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (51 analysts) rates it buy, with a mean price target of $535. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-21Markup$190.34-9.3%Entry 7
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (51 analysts) rates it buy, with a mean price target of $535. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-20Markup$209.86+0.0%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 39%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (51 analysts) rates it buy, with a mean price target of $535. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
